Europe HLA Typing Market (2025-2030)
The Europe HLA Typing Market was valued at $371.5 Million in 2025 and projected to reach to $494.5 Million by 2030, representing a compound annual growth rate of 5.9%. Europe's HLA typing market is poised for sustained growth through 2030, supported by an aging population with increasing transplantation needs and rising autoimmune disease prevalence.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe HLA Typing Market Trends and Insights
- This growth in Europe reflects increasing demand for organ transplantation, rising prevalence of autoimmune disorders, and strengthening healthcare infrastructure across the region.
- Europe's mature healthcare systems and regulatory frameworks support adoption of advanced HLA typing technologies for improved patient outcomes. The HLA typing market in Europe is driven by growing investment in precision medicine and immunogenomics research.
- Europe's commitment to transplant programs and disease management protocols continues to fuel demand for accurate HLA testing solutions.
- Between 2025 and 2030, Europe is expected to maintain steady market expansion as healthcare providers increasingly integrate HLA typing into clinical workflows for transplantation, disease diagnosis, and treatment planning..
Key Market Statistics
- CAGR (2025-2030) 5.9% CAGR
- Market Size, 2025 ~USD 371.5 Million
- Forecast, 2030 ~USD 494.5 Million
- Geography Europe
Europe HLA Typing Market Overview
Market Valuation & Growth Trajectory :
Europe's HLA typing market is valued at $371.5 million in 2025 and is projected to reach $494.5 million by 2030, representing a steady CAGR of 5.9%, driven by robust healthcare infrastructure and regulatory frameworks across the region.
Germany Leads European Market :
Germany dominates the European HLA typing market with a market size of $275.86 million, reflecting its advanced healthcare system, high transplantation rates, and strong investment in diagnostic technologies and immunological testing.
Rising Transplantation Demand :
Increasing prevalence of organ failure and autoimmune disorders across Europe is driving demand for HLA typing services, essential for successful organ transplantation matching and reducing rejection risks in recipient populations.
Regulatory Excellence & Innovation :
Europe's stringent regulatory standards and emphasis on precision medicine are accelerating adoption of advanced HLA typing technologies, including next-generation sequencing and molecular-based diagnostic platforms across major healthcare systems.
Europe HLA Typing Market Dynamics
- The region's mature healthcare infrastructure, coupled with strong regulatory oversight and reimbursement policies, creates a favorable environment for market expansion.
- Key European markets including Germany, UK, and France are investing heavily in advanced diagnostic capabilities and precision medicine initiatives. The market will benefit from technological advancements in molecular HLA typing, increased awareness among healthcare providers, and growing collaboration between transplant centers and diagnostic laboratories.
- Additionally, European Union directives promoting organ donation and transplantation standardization will further accelerate market growth, positioning Europe as a critical hub for HLA typing innovation and clinical implementation through the forecast period..
Related Ecosystem
Key Takeaways
- Europe's HLA typing market is valued at $371.5 million in 2025 and will reach $494.5 million by 2030, growing at 5.9% CAGR.
- Europe's mature healthcare infrastructure and strong transplant programs drive consistent demand for HLA typing solutions.
- Precision medicine initiatives and immunogenomics research investments accelerate HLA typing adoption across Europe.
- Europe's regulatory environment and clinical integration standards support sustained market growth through 2030.
HLA Typing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | COMMERCIAL SERVICE PROVIDERS (End User) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 6% from 2025 to 2030 |
| Largest Segment | DIAGNOSTIC APPLICATIONS (Application) |
| Market Size Base Year (Billions) | ~USD 1.72 (2025) |
| Revenue Forecast (Billions) | ~USD 2.3 (2030) |
| Segments Covered | Product & Service, Technology, Type, Application, End User, Diagnostic Application |
Europe HLA Typing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Consumables
- Software & Services
By Technology
- Molecular Assay Technologies
- Non-Molecular Assay Technologies
By Type
- Cancer Diagnosis & Prevention
- Donor-Recipient Cross-Matching
- Infectious Disease Testing
- Next-Generation Sequencing
- Other Diagnostic Applications
- Other Pcr-Based Molecular Assays
- Other Sequencing-Based Molecular Assays
- Pcr-Based Molecular Assays
- Real-Time Pcr
- Sanger Sequencing
- Sequence-Specific Oligonucleotide-Pcr
- Sequence-Specific Primar-Pcr
- Sequence-Specific Primer-Pcr
- Sequencing-Based Molecular Assays
- Transfusion Therapy
By Application
- Diagnostic Applications
- Research Applications
By End User
- Commercial Service Providers
- Hospitals & Transplant Centers
- Research Laboratories & Academic Institutes
By Diagnostic Application
- Cancer Diagnosis & Prevention
- Donor-Recipient Cross-Matching
- Infectious Disease Testing
- Other Diagnostic Applications
- Transfusion Therapy
EUROPE: HLA TYPING MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| COMMERCIAL SERVICE PROVIDERS | 291.74 | 307.43 | 323.77 | 342.6 | 362.85 | 385.02 | 409.69 | 436.35 | 6.1 |
| HOSPITALS & TRANSPLANT CENTERS | 154.39 | 160.74 | 167.24 | 174.82 | 182.89 | 191.69 | 201.46 | 211.91 | 4.8 |
| RESEARCH LABORATORIES & ACADEMIC INSTITUTES | 19.37 | 19.75 | 20.11 | 20.56 | 21.01 | 21.49 | 22.01 | 22.54 | 2.3 |
| TOTAL | 465.49 | 487.93 | 511.13 | 537.97 | 566.75 | 598.2 | 633.17 | 670.81 | 5.6 |
Target Audience
- In Vitro Diagnostics (IVD) Manufacturers : Require detailed European market data to develop HLA typing assays, optimize product portfolios for regional regulatory requirements, and identify distribution partnerships across major European healthcare systems.
- Transplant Centers & Hospital Networks : Need market intelligence on HLA typing technologies, best practices, and cost-effectiveness data to enhance transplantation programs, improve patient outcomes, and optimize laboratory operations across Europe.
- Healthcare Investors & Private Equity : Seek comprehensive market analysis and growth forecasts for Europe to evaluate investment opportunities in diagnostic companies, laboratory networks, and precision medicine platforms with strong regional potential.
- Clinical Laboratory Operators : Require insights into European market trends, reimbursement models, and technology adoption rates to guide service expansion, equipment investments, and competitive positioning in their respective markets.
- Healthcare Policy & Regulatory Bodies : Need market data and trend analysis to inform transplantation policies, diagnostic standards, and healthcare resource allocation decisions that support improved patient access to HLA typing services across Europe.
Key Companies in the Europe HLA Typing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BGI GENOMICS | China | Public Company | Sequencing-based HLA services (NGS, immune repertoire, WES/WGS-derived typing),Reagents & consumables for HLA workflows,Instruments (sequencers and related hardware used for HLA), |
| BECTON DICKINSON AND CO | United States | Public Company | Instruments,Reagents,Software, |
| BD | United States | Public Company | Instruments,Reagents,Software, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Sequencing-based HLA (NGS, Sanger),PCR-based HLA (SSO, SSP, Real-time),Software and Informatics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing Instruments (NGS platforms used for HLA typing),Sequencing Reagents, Flow Cells, and Library Prep for HLA,Software and DRAGEN-based Secondary Analysis for HLA, |
| QIAGEN | Netherlands | Public Company | Reagents & Consumables (PCR, NGS, sample technologies for HLA workflows),Instruments (PCR, NGS-related, automation, QC),Software & Bioinformatics (HLA analysis, SaaS, interpretation), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Reagents & Consumables (PCR and sequencing HLA kits),Instruments (PCR, sequencing-adjacent, and automation),Software & Informatics (HLA analysis, LIS connectivity), |
| F. HOFFMANN-LA ROCHE LTD | United States | ||
| CAREDX, INC. | United States | Public Company | HLA Typing Reagents & Assays (PCR SSO/SSP, Real-time, NGS, Sanger),Instruments & NGS Workflow Components,Software (Ottr, HLA Data Systems, XynQAPI, MedActionPlan, others), |
| DIASORIN S.P.A. | Italy | Public Company | Instruments,Reagents,Software, |
| EUROBIO SCIENTIFIC | France | Public Company | Reagents (PCR and NGS HLA typing),Software (HLA typing analysis and reporting),Instruments (sequencers, ancillary lab systems), |
BGI GENOMICS
BGI Genomics is a Chinese public company founded in 1999 that employs 3,580 people. The company operates in the genomics and genetic sequencing sector.
BECTON DICKINSON AND CO
Becton Dickinson and Co is a United States-based public company founded in 1897 with 72,000 employees. The company operates in the medical devices and diagnostics sector.
BD
BD is a United States-based public company founded in 1897 with 72,000 employees. The company operates in the medical devices and diagnostics sector.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company operates in the life sciences and diagnostics industry.
ILLUMINA, INC.
Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees. The company specializes in DNA sequencing and genetic analysis technologies.
QIAGEN
QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. The company operates in the molecular diagnostics and life sciences sector.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.
F. HOFFMANN-LA ROCHE LTD
Insufficient data available to provide a business description for this company.
CAREDX, INC.
CareDx, Inc. is a United States-based public company founded in 1998 with 763 employees. The company operates in the molecular diagnostics and transplant monitoring sector.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italy-based public company founded in 1968 with 3,242 employees. The company specializes in diagnostic solutions and immunoassay products.
EUROBIO SCIENTIFIC
Eurobio Scientific is a France-based public company founded in 1997 with 343 employees. The company operates in the life sciences and diagnostics industry.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 275.86 Million |
| UK | USD 209.22 Million |
| France | USD 131.9 Million |
| Spain | USD 25.3 Million |
| Italy | USD 16.9 Million |
| Rest Of Europe | USD 11.6 Million |
Country market size visualization
Reasons to Buy this Report
- Country-Level Market Segmentation : Access detailed market sizing for Germany ($275.86M), UK ($209.22M), France ($131.9M), Spain, and Italy, enabling precise market entry strategies and competitive positioning across Europe's diverse healthcare landscapes.
- Transplantation Trend Analysis : Understand regional variations in organ transplantation rates, HLA typing adoption patterns, and clinical protocols across European countries to identify high-growth opportunities and market gaps.
- Regulatory & Reimbursement Insights : Gain intelligence on European regulatory frameworks, CE marking requirements, and reimbursement policies that influence HLA typing adoption and pricing strategies across different national healthcare systems.
- Competitive Landscape Mapping : Identify leading diagnostic providers, technology platforms, and market consolidation trends specific to Europe, supporting strategic partnerships and acquisition planning in the region.
- Growth Forecasting & Investment Planning : Leverage 5-year projections and CAGR analysis to inform capital allocation, R&D investment decisions, and market expansion timelines tailored to European market dynamics and healthcare priorities.
Frequently asked questions
What is the current size of the HLA typing market in Europe?
Europe's HLA typing market is valued at $371.5 million in 2025 and is expected to grow to $494.5 million by 2030.
What is the growth rate of the HLA typing market in Europe?
Europe's HLA typing market is growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2030.
What factors are driving HLA typing market growth in Europe?
Key drivers in Europe include increased organ transplantation demand, rising autoimmune disorder prevalence, precision medicine adoption, and strong healthcare infrastructure investment.
Which European countries lead the HLA typing market?
Europe's largest markets include Germany, France, the United Kingdom, and other Western European nations with advanced healthcare systems and high transplant volumes.
How does Europe's HLA typing market compare to global trends?
Europe's 5.9% CAGR is slightly below the global 6% CAGR, reflecting Europe's mature market status and steady, sustainable growth trajectory.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and gather valuable information for analyzing the global HLA typing market. Additionally, in-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from leading market players, and industry consultants. These interviews helped obtain and validate critical qualitative and quantitative data while assessing the growth prospects. The global market size, initially estimated through secondary research, was then refined and finalized through triangulation with insights from primary research.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the HLA typing market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various companies and organizations in the HLA typing market. The primary sources from the demand side include OEMs, private and contract testing organizations, and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The bottom-up approach was used to estimate and validate the total size of the HLA typing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- A list of the major global players operating in the HLA typing market was generated.
- Mapping annual revenues generated by major global players from the HLA typing segment (or nearest reported business unit/service category)
- Revenue mapping of key players to cover a major share of the global market as of 2024
- Extrapolating the global value of the HLA Typing industry
Global HLA Typing Market Size: Bottom-up Approach and Top-down Approach
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
HLA typing is a genetic procedure to determine donor-recipient compatibility, cancer & autoimmune disorder diagnosis, pathogen testing, and transfusion therapy. Additionally, it is used in drug testing, disputed paternity, and anthropological studies. Advanced genomic techniques, such as PCR and NGS, are increasingly being used in HLA typing, apart from serological and other conventional techniques for immuno-compatibility testing.
Stakeholders
- HLA Typing Product Manufacturers
- Healthcare Service Providers (Hospitals, Transplant Centers, and Blood Transfusion Centers)
- Blood, Tissue, and Stem Cell Banks
- Government Organizations
- Independent Associations and Regulatory Authorities
- R&D Companies
- Independent Reference Laboratories
- Diagnostic Laboratories
- Clinical Research Organizations
- Research Laboratories and Academic Institutes
Report Objectives
- To define, describe, and forecast the HLA typing market based on technology, product & service, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth potential of the global HLA typing market (drivers, restraints, opportunities, challenges, and trends)
- To analyze the micro markets with respect to individual growth trends, future prospects, and contributions to the global HLA typing market
- To analyze key growth opportunities in the global HLA typing market for key stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa (GCC Countries and Rest of Middle East & Africa)
- To profile the key players in the HLA typing market and comprehensively analyze their market shares and core competencies
- To track and analyze the competitive developments undertaken in the global HLA typing market, such as agreements, expansions, and acquisitions
Get the Full HLA Typing Market Report
Full forecast, segment splits, and company analysis for all HLA Typing Market.
- Canada HLA Typing Market
- US HLA Typing Market
- Germany HLA Typing Market
- UK HLA Typing Market
- France HLA Typing Market
- Spain HLA Typing Market
- Italy HLA Typing Market
- China HLA Typing Market
- Japan HLA Typing Market
- India HLA Typing Market
- South Korea HLA Typing Market
- Australia HLA Typing Market
- Brazil HLA Typing Market
- Mexico HLA Typing Market
- Rest Of Europe HLA Typing Market
- Rest Of Asia HLA Typing Market
- Rest Of Latin America HLA Typing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
